“Doc, why do I have bone disease after kidney transplantation?”
Mineral and bone disorders are frequently found after kidney transplantation. Determining what is occurring in the bone of a transplant patient is exceedingly complicated as it involves pre-transplant...
View ArticleSCM13: Interview with Dr. Ashtar Chami
Dr. Ashtar Chami (AC), from Emory University Hospital, discusses her abstract for the National Kidney Foundation’s 2013 Spring Clinical Meetings (SCM13), Autosomal Dominant Polycystic Kidney Disease...
View ArticleATC 2013: Development of De Novo HLA Antibodies After Transplantation –...
Development of De Novo HLA antibodies after transplantation: Results from the CTOT02 Study. CTOT02 is a large prospective multi-center trial set in 2 phases. Phase 1 involved screening of unsensitized...
View ArticleShould We Pay Our Donors? – Financial Incentives for Donation, Part 1
Fig 1 from Gill et al. © National Kidney Foundation In a recent article in AJKD, Gill and colleagues discuss the possibility of implementing financial incentives to increase organ donation in Canada....
View ArticleShould We Pay Our Donors? – Financial Incentives for Donation, Part 2
In the second of two parts, Dr. John Gill (JG) continues to discuss his paper about using financial incentives to increase organ donation in Canada with Dr. Vinay Nair (eAJKD), eAJKD Advisory Board...
View ArticleParaprotein Mediated Disease Following Kidney Transplantation
Fig 1 Batal et al AJKD, ©National Kidney Foundation In a recent article published by AJKD, Batal et al describe a patient whose kidney allograft biopsy 7 years after transplantation revealed IgG1 kappa...
View ArticleThe Expanding Role of Proteasome Inhibitors in Treatment of Renal Diseases
Invited commentary by Dr. Parmjeet Randhawa Fig 1A Patel et al AJKD, © National Kidney Foundation. Bortezomib is a proteasome inhibitor initially licensed for use in patients with refractory multiple...
View ArticleATC2015: Blocking B7 in Kidney Transplantation, Is It Effective in Preventing...
The American Transplant Congress (ATC) is the joint annual meeting of the American Society of Transplant Surgeons (ASTS) and the American Society of Transplantation (AST) and is taking place in...
View ArticleATC2015: Biomarkers in Transplantation
Biomarkers are always a hot topic in transplantation. At the ATC, Dr. Barbara Murphy, from the Icahn School of Medicine at Mt. Sinai, gave an intriguing discussion on molecular biomarkers developed as...
View ArticleATC2015: Antibodies and Allograft Injury
There were two fascinating talks about the use of C1q modified Luminex assay to assess for complement fixing antibodies both before and after kidney transplantation. Prior studies, including one...
View ArticleATC2015: Belatacept in Kidney Transplantation
There were several abstracts presented about outcomes in patients treated with belatacept, a recently FDA-approved immunosuppressive agent that blocks T-cell activation. Belatacept inhibits T cell...
View ArticleGout After Living Kidney Donation: Another Unrecognized Risk?
Copyright: joloei/123RF Stock Photo In an article recently published in AJKD, Lam et al describe the risk of gout in 1988 living kidney donors compared to a matched cohort of 19,880 non-donors over a...
View ArticleTest Your Knowledge: Immunology and Transplantation
Fig 6 from Hricik, AJKD, © National Kidney Foundation. AJKD recently published a Core Curriculum by Dr. Donald Hricik on transplant immunology and immunosuppression. The following questions based on...
View ArticlePaying Kidney Donors — Necessary or Not?
Copyright: raywoo / 123RF Stock Photo There is a great shortage of transplantable kidneys based on the number of transplant candidates awaiting organs in the United States. Some thought leaders have...
View Article#SCM16: Eculizumab and Bortezomib Combination – Can It Work?
Dr. Yougandhar Akula (YA), from the University of Mississippi in Jackson, Mississippi, discusses his abstract for the National Kidney Foundation’s 2016 Spring Clinical Meetings (SCM16), Eculizumab with...
View Article#SCM16: Tele-Nephrology
Dr. Desiree Garcia-Anton (DG), from the University of Miami and Miami VA Medical Center in Miami, Florida, discusses her abstract for the National Kidney Foundation’s 2016 Spring Clinical Meetings...
View ArticleLCP-Tacrolimus: A Novel Extended-Release Tacrolimus for Use in Kidney...
Copyright: areeya / 123RF Stock Photo Tacrolimus is the cornerstone of immunosuppression in solid organ transplantation. The SRTR annual data report from 2014 suggests that > 90% of kidney...
View ArticleRole of Donor Pre-Implantation Biopsies in Kidney Transplantation
PathPointers is a new type of blog post that will highlight important everyday teaching points when reviewing kidney histology. These blog posts will be brief and easy-to-read, using real clinical...
View ArticleASERTAA: Towards Optimizing Tacrolimus-based Immunosuppression in African...
Tacrolimus was first discovered by scientists of the Fujisawa Pharmaceutical Company in a soil sample taken from the foot of Mount Tsukuba in Tokyo. Originally called FR000506 and later FK-506, the...
View ArticleHow Did Northern Ireland Revolutionize Their Living Kidney Donor...
A recent article published in AJKD by Graham and Courtney describes a quality improvement project in Belfast City Hospital to facilitate living kidney donation. Prior to 2010, this center had low rates...
View Article
More Pages to Explore .....